| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
The population of CKD patients in Japan is estimated as 13.3 million people. CKD is a risk factor of end-stage renal disease as well as cardiovascular disorders. In the present study, we examined the functional role of Vasohibin-1, a negative feedback regulator of angiogenesis, in CKD and its potential therapeutic effects. Adenoviral transfer of Vasohibin-1 resulted in the amelioration of renal alterations in experimental models of mouse type 1 and 2 diabetic nephropathy. Vasohibin-1 exhibited anti-angiogenic effects as well as direct therapeutic effects on mesangial cells and podocytes. These results suggest the potential therapeutic efficacy of Vasohibin-1 in CKD.
|
